Transplant center directory

Adult autologous and allogeneic stem cell transplants, with active protocols for myeloablative, non-myeloablative and reduced intensity transplants, non-myeloablative and myeloablative cord protocols and haploidentical transplants. Limited pediatric patients (ages 16 to 18): autologous for Hodgkin's disease protocol and related allogeneic for aplastic anemia . CAR-T cell therapy for the diagnosis of ALL for 18-25 year old patients and NHL and we also offer CAR-T for Mantle Cell lymphoma, Follicular Lymphoma, and Multiple Myeloma.

This center has been performing allogeneic transplants since 1992 and has been an NMDP/Be The Match transplant center since June 1997.

This center's actual 1-year survival results are similar to the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 75 patients.

The actual 1-year survival of these patients is 71.9%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 65.0% and 83.8%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.